49. Systemic lupus erythematosus Clinical trials / Disease details


Clinical trials : 946 Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01085097
(ClinicalTrials.gov)
September 1, 20104/3/2010A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus NephritisA Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)Lupus NephritisDrug: Laquinimod;Drug: Mycophenolate Mofetil;Drug: Prednisolone/Prednisone;Drug: Placebo;Drug: MethylprednisoloneTeva Branded Pharmaceutical Products R&D, Inc.NULLCompleted18 Years75 YearsAll46Phase 2United States;Canada;France;Russian Federation;United Kingdom
2NCT01085084
(ClinicalTrials.gov)
July 20109/3/2010Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus ArthritisA Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus ArthritisLupus ArthritisDrug: Laquinimod;Other: PlaceboTeva Pharmaceutical IndustriesNULLCompleted18 Years75 YearsBoth82Phase 2United States;Canada